Coadministration of Liraglutide With Tacrolimus in Kidney Transplant Recipients: A Case Series
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Glucocorticoids commonly used in the posttransplant period have been demonstrated to reduce insulin sensitivity, impair α-cell function, and more recently, impair β-cell function and the incretin effect (1). Liraglutide is an incretin mimetic approved for the treatment of type 2 diabetes. One major concern about the use of liraglutide after transplantation is that it delays gastric emptying, which could potentially affect absorption of coadministered oral medications, such as tacrolimus, which has a narrow therapeutic index (2). This case series is the first to report on the safety of this drug combination in kidney transplant recipients (KTRs). Nonpregnant, adult (≥18 years of age), and clinically stable (estimated glomerular filtration rate [eGFR] ≥60 mL/min/1.73 m2 and not experiencing allograft rejection or two serum creatinine values >30% of each other obtained at least 1 week apart within 4 weeks prior to enrollment) KTRs receiving unchanged tacrolimus doses for ≥4 weeks (goal trough concentration 5–15 …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Fair quality of methodology was considered in studies that enrolled only male subjects (“population” category) [14, 22, 25, 26, 28] or when blood sampling did not coincide with a steady state of an investigated drug [13–17, 19, 24].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Coadministration of liraglutide and tacrolimus in five kidney transplant recipients resulted in reduced AUC of the latter, but trough levels remained unaltered [26].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The number of subjects was small in one study that was rated poor quality for “sample” [26].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of renal impairment on the pharmacokinetics of the GLP‐1 analogue liraglutide
Jacobsen, L. V., Hindsberger, C., Robson, R., & Zdravkovic, M. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03536.x · Cited by 215 · cited 1×
“Evidence for the use of liraglutide in patients with chronic kidney disease is limited (4,5).”
Backgroundvan Raalte, D. H., van Genugten, R. E., Linssen, M. M. L., Ouwens, D. M., & Diamant, M. (2011) · Diabetes Care · doi:10.2337/dc10-1677 · Cited by 150 · cited 1×
“G lucocorticoids commonly used in the posttransplant period have been demonstrated to reduce insulin sensitivity, impair a-cell function, and more recently, impair b-cell function and the incretin effect (1).”
BackgroundMild Renal Impairment and the Efficacy and Safety of Liraglutide
Davidson, J. A., Brett, J., Falahati, A., & Scott, D. (2010) · Endocrine Practice · doi:10.4158/ep10215.or · Cited by 88
Barraclough, K. A., Isbel, N. M., Kirkpatrick, C. M. J., Lee, K., Taylor, P. J., Johnson, D. W., Campbell, S. B., Leary, D. R., & Staatz, C. E. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03815.x · Cited by 53 · cited 1×
“Tacrolimus area under the curve (AUC)0–12h was measured with a previously validated multiple regression– derived limited sampling strategy (3).”
MethodIncretin-based Therapy in Chronic Kidney Disease
Pinelli, N. R., Moore, C. L., & Tomasello, S. (2010) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2010.06.003 · Cited by 13
Self-citation
Cited by
Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes
Shivaswamy, V., Boerner, B., & Larsen, J. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1084 · Cited by 328
International consensus on post-transplantation diabetes mellitus
Sharif, A., Chakkera, H. A., de Vries, A. P. J., Eller, K., Guthoff, M., Haller, M. C., Hornum, M., Nordheim, E., Kautzky‐Willer, A., Krebs, M., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad258 · Cited by 145
Management of post‐transplant diabetes: immunosuppression, early prevention, and novel antidiabetics
Hecking, M., Sharif, A., Eller, K., & Jenssen, T. G. (2020) · Transplant International · doi:10.1111/tri.13783 · Cited by 125
Thangavelu, T., Lyden, E., & Shivaswamy, V. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00786-1 · Cited by 96
Calvarysky, B., Dotan, I., Shepshelovich, D., Leader, A., & Cohen, T. D. (2024) · Drug Safety · doi:10.1007/s40264-023-01392-3 · Cited by 97
“Fair quality of methodology was considered in studies that enrolled only male subjects (“population” category) [14, 22, 25, 26, 28] or when blood sampling did not coincide with a steady state of an investigated drug [13–17, 19, 24].”
BackgroundInfluentialPost-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment
Peláez-Jaramillo, M. J., Cárdenas-Mojica, A. A., Gaete, P. V., & Mendivil, C. O. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0374-8 · Cited by 89
“One case series of five kidney transplant recipients with post-transplant diabetes reported the safety of liraglutide administered for 21 days, without changes in tacrolimus levels [149].”
BackgroundPost-transplantation diabetes—state of the art
Sharif, A., & Cohney, S. J. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00387-3 · Cited by 99
Singh, P., Pesavento, T. E., Washburn, K., Walsh, D., & Meng, S. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13619 · Cited by 86
The use of GLP1R agonists for the treatment of type 2 diabetes in kidney transplant recipients
Kukla, A., Hill, J., Merzkani, M., Bentall, A., Lorenz, E. C., Park, W. D., D’Costa, M., Kudva, Y. C., Stegall, M. D., & Shah, P. (2020) · Transplantation Direct · doi:10.1097/txd.0000000000000971 · Cited by 73
Conte, C., & Secchi, A. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1137-8 · Cited by 81
Post-Transplantation Diabetes Mellitus
Ahmed, S. H., Biddle, K., Augustine, T., & Azmi, S. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00790-5 · Cited by 77
“A case series demonstrated that tacrolimus trough levels are not affected by co-administration of liraglutide [112].”
BackgroundMetabolic Disorders with Kidney Transplant
Cohen, E., Korah, M. M., Callender, G. G., Aguiar, R. B. D., & Haakinson, D. J. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09310819 · Cited by 65
Liou, J.-H., Liu, Y.-M., & Chen, C.-H. (2018) · Transplantation Proceedings · doi:10.1016/j.transproceed.2018.03.087 · Cited by 55
Vanhove, T., Remijsen, Q., Kuypers, D. R. J., & Gillard, P. (2016) · Transplantation Reviews · doi:10.1016/j.trre.2016.09.001 · Cited by 56
“019), although trough levels were not affected [90].”
BackgroundDiabetes Care After Transplant
Wallia, A., Illuri, V., & Molitch, M. E. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.01.005 · Cited by 50
Krisanapan, P., Suppadungsuk, S., Sanpawithayakul, K., Thongprayoon, C., Pattharanitima, P., Tangpanithandee, S., Mao, M. A., Miao, J., & Cheungpasitporn, W. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae018 · Cited by 49
“Regarding baseline kidney function, the mean serum creatinine was 1.2 ± 0.4 mg/dl ( from 79 participants across five studies [12 , 43 –45 , 48 ]) , the eGFR was 50.8 ± 18.7 ml/min/1.73 m 2 ( from 252 participants across six studies [12 , 43 –45 , 47 , 50 ]) and the UPCR was 0.16 ± 0.74 g/g ( from…”
BackgroundInfluentialPost-transplant diabetes mellitus following heart transplantation
Newman, J. D., Schlendorf, K. H., Cox, Z. L., ZALAWADIYA, S. K., Powers, A. C., Niswender, K. D., Shah, R. V., & Lindenfeld, J. M. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.07.011 · Cited by 49
Non-immunological complications following kidney transplantation
Cohen‐Bucay, A., Gordon, C. E., & Francis, J. M. (2019) · F1000Research · doi:10.12688/f1000research.16627.1 · Cited by 49
Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review
Cehic, M. G., Nundlall, N., Greenfield, J. R., & Macdonald, P. S. (2018) · Journal of Transplantation · doi:10.1155/2018/1025893 · Cited by 42
“Regarding the use of GLP-1 agonists for PTDM management following solid-organ transplantation, only two case series examining liraglutide therapy in kidney [96] and pancreas [97] transplantation exist, totalling 11 patients.”
BackgroundManagement of diabetes mellitus in patients undergoing liver transplantation
Grancini, V., Resi, V., Palmieri, E., Pugliese, G., & Orsi, E. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.042 · Cited by 36
“Nevertheless, drug exposure, the most relevant pharmacokinetic parameter, was not found to be reduced in parallel with gastric emptying [227,228] and this was also the case with liraglutide therapy [229].”
ResultLin, L., Chen, J., Huang, T. T.-M., & Wu, V. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02649-0 · Cited by 36
Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients
Anderson, S., Cotiguala, L., Tischer, S. M., Park, J. M., & McMurry, K. A. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020951955 · Cited by 28
Hyperglycemia management in patients with posttransplantation diabetes
Galindo, R. J., Fried, M., Breen, T., & Tamler, R. (2016) · Endocrine Practice · doi:10.4158/ep151039.ra · Cited by 25
Obesity and Post-Transplant Diabetes Mellitus in Kidney Transplantation
Martín-Moreno, P. L., Shin, H. S., & Chandraker, A. K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112497 · Cited by 25
Early Post-Renal Transplant Hyperglycemia
Iqbal, A., Zhou, K., Kashyap, S. R., & Lansang, M. C. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab697 · Cited by 31
Berković, M. C., Virović-Jukić, L., Bilić-Čurčić, I., & Mrzljak, A. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i21.2740 · Cited by 25
Oikonomaki, D., Dounousi, E. C., Duni, Α., Roumeliotis, S. K., & Liakopoulos, V. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108604 · Cited by 26
Ertuğlu, L. A., Porrini, E., Hornum, M., Demiray, A., Afşar, B., Ortíz, A., Covic, A. C., Rossing, P. R., & Kanbay, M. (2021) · Transplant International · doi:10.1111/tri.13883 · Cited by 26
“Reported side effects included nausea, headache, and decreased appetite [79].”
BackgroundRecent advances in new-onset diabetes mellitus after kidney transplantation
Montada-Atin, T., & Prasad, G. V. R. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i5.541 · Cited by 24
Institutional Experience With New Antidiabetic Drugs in Kidney Transplant
González, A. Y., Kanter, J., Sancho, A., Gavela, E., Solá, E., Ávila, A., & Pallardó, L. (2021) · Transplantation Proceedings · doi:10.1016/j.transproceed.2021.08.042 · Cited by 25
Lawrence, S. E., Chandran, M. M., Park, J. M., Sweiss, H., Jensen, T. B., Choksi, P. U., & Crowther, B. R. (2023) · Clinical Transplantation · doi:10.1111/ctr.14922 · Cited by 23
Guthoff, M., Vosseler, D., Langanke, J., Nadalin, S., Königsrainer, A., Häring, H., Fritsche, A., & Heyne, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134971 · Cited by 23
“Potential limitations include altered adsorption of immunosuppression, although a recently published small case series indicates that coadministration of the incretin analogue liraglutide with tacrolimus may be safe [39].”
BackgroundManagement of post-transplant diabetes mellitus: an opportunity for novel therapeutics
Montero, N., Oliveras, L., Soler, M. J., & Cruzado, J. M. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab131 · Cited by 25
“[17] • Case series, n1⁄45 • Follow-up: 3 weeks KT recipients with or”
BackgroundSadhu, A., Schwartz, S. S., & Herman, M. E. (2015) · Endocrine Practice · doi:10.4158/ep14569.ra · Cited by 23
“In a small group of patients, coadministration of liraglutide with tacrolimus improved postprandial glucose and engendered weight reduction without clinically altering trough tacrolimus concentrations in stable kidney transplant recipients with mild renal impairment (65).”
Brown, S. A., Izzy, M. J., & Watt, K. D. S. (2020) · Hepatology · doi:10.1002/hep.31595 · Cited by 20
Diabetes mellitus in dialysis and renal transplantation
Ben-David, E., Hull, R., & Banerjee, D. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211048663 · Cited by 23
Diabetes in Kidney Transplantation
Cantarin, M. P. M. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.10.004 · Cited by 18
Liraglutide in whole-pancreas transplant patients with impaired glucose homoeostasis: A case series
Cariou, B., Bernard, C., & Cantarovich, D. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.10.004 · Cited by 17
Endocrine effects of long-term calcineurin inhibitor use in solid organ transplant recipients
Diker‐Cohen, T., Dotan, I., Calvarysky, B., & Robenshtok, E. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf182 · Cited by 19
Tsai, S., & Chen, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133152 · Cited by 16
Bellanca, C. M., Augello, E., Benedetto, G. D., Burgaletto, C., Cantone, A. F., Cantarella, G., Bernardini, R., Polosa, R., & the DiaSmokeFree Working Group (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1406860 · Cited by 17
Rudzki, G., Knop-Chodyła, K., Piasecka, Z., Kochanowska-Mazurek, A., Głaz, A., Wesołek, E., & Woźniak, M. M. (2024) · Pharmaceuticals · doi:10.3390/ph17080987 · Cited by 20
Sridhar, V. S., Ambinathan, J. P. N., Gillard, P., Mathieu, C., Cherney, D. Z. I., Lytvyn, Y., & Singh, S. K. (2021) · Transplantation · doi:10.1097/tp.0000000000003919 · Cited by 15
Antidiabetic therapy in post kidney transplantation diabetes mellitus
Werzowa, J. M., Säemann, M. D., Haidinger, M., Krebs, M., & Hecking, M. (2015) · Transplantation Reviews · doi:10.1016/j.trre.2015.01.001 · Cited by 14
Diker‐Cohen, T., Rudman, Y., Turjeman, ., Akirov, A., Steinmetz, T., Calvarysky, B., & Dotan, I. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101624 · Cited by 16
Post-Transplant Diabetes: Prevalence, Risk, and Management Challenges
Bashier, A. M., Kumar, D., Alalawi, F. J. A., Alnour, H. H., Alhadari, A. K., & Hussain, A. A. B. (2022) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000522092 · Cited by 11
Renal posttransplantation diabetes mellitus: An overview
Pimentel, A. L., Bauer, A. C., & Camargo, J. L. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.09.010 · Cited by 13
Riehl-Tonn, V. J., Medak, K. D., Rampersad, C., MacPhee, A., & Harrison, T. G. (2024) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581241290317 · Cited by 12
Phillips, J., Chen, J. H. C., Ooi, E. M. M., Prunster, J., & Lim, W. H. (2021) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2021.731574 · Cited by 11
Usman, M., Yu, H., Chen, X., Zhan, Y., Lai, C., & Xu, K. (2025) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.24.271 · Cited by 8
“The analysis of SOTs [20,28,31,39], KTRs [12,29,32–38], and heart transplant [30] showed a significant reduction in weight, with an MD of –2.56 kg (95% CI, –4.06 to –1.06; p < 0.01, I 2 = 37%), –3.91 kg (95% CI, –5.45 to –2.37; p < 0.01, I 2 = 0%), and –12.33 kg (95% CI, –19.63 to –5.03),…”
InfluentialAleksić, S., Eisenberg, R. E., Tsomos, E., Anaraki, S. Z., Japp, E., Upadhyay, L., Mowrey, W. B., Akalin, E., & Zonszein, J. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108221 · Cited by 7
GLP-1 receptor agonists for kidney transplant recipients
Schmitz, S. H., & Orandi, B. J. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf199 · Cited by 9
Huang, Y., Tsou, M., Li, P., Chen, J., Liu, Y., Meyerowitz‐Katz, G., Tsai, T., & Su, P. (2025) · Advanced Science · doi:10.1002/advs.202518813 · Cited by 8
Novel Drugs for the Management of Diabetes Kidney Transplant Patients: A Literature Review
Valencia-Morales, N. D., Cubillo, B. R., Loayza-López, R. K., de la Higuera, M. Á. M., & Sánchez-Fructuoso, A. I. (2023) · Life · doi:10.3390/life13061265 · Cited by 7
Oral semaglutide in kidney transplant recipients with metabolic syndrome: three Japanese cases
Miyazaki, R., & Miyagi, K. (2023) · Renal Replacement Therapy · doi:10.1186/s41100-023-00492-1 · Cited by 5
Glucagon-like peptide and its receptor agonists for the treatment of rheumatic diseases
Chamchoum, E., Katrib, N., Nassif, N., Ratel, Y., & Rida, M. A. (2025) · World Journal of Experimental Medicine · doi:10.5493/wjem.v15.i3.107020 · Cited by 7
Freitas, J. C., Silvano, J., Ribeiro, C., Malheiro, J., Pedroso, S., Almeida, M., Fonseca, I. M., & Martins, L. S. (2024) · Brazilian Journal of Transplantation · doi:10.53855/bjt.v27i1.563_eng · Cited by 7
Sanyal, D., Biswas, M., & Chaudhari, N. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.11.019 · Cited by 4
Key challenges of post-liver transplant weight management
Berković, M. C., Šeša, V., Balen, I., Lai, Q., Silovski, H., & Mrzljak, A. (2024) · World Journal of Transplantation · doi:10.5500/wjt.v14.i4.95033 · Cited by 5
“…of gastric emptying which could potentially alter the absorption of immunosuppressants, but data from small case series where liraglutide, one of the most widely prescribed GLP-1RA, was concomitantly used with tacrolimus did not show any clinically significant alterations in tacrolimus levels [34].”
Can GLP-1RAs redefine transplantation standard of care?
Almalki, B. A. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.08.013 · Cited by 6
Navarrete, R. E. T., Freitas, J. C., Fonseca, I. M., Cunha, A., Sa, J. R., & Martins, L. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010181 · Cited by 3
“Hypoglycemia was reported in 6 patients (7%), all using concomitant insulin, consistent with observations by Pinelli et al. [30] and Liou et al. [31] regarding increased hypoglycemia risk with insulin combined with SGLT2is or GLP-1 RAs in transplant recipients.”
Post Kidney Transplant: Obesity
Kaur, G., & Yerram, P. (2018) · Springer eBooks · doi:10.1007/978-3-030-00132-2_11 · Cited by 3
Novel Glucose-Lowering Therapies in the Setting of Solid Organ Transplantation
Nissaisorakarn, P., Pavlakis, M., & Aala, A. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.03.001 · Cited by 3
Corrêa, L. M. D. A., Mazur, G. R., Santiago, C. B. G., Dante, L. E., Marco, P. S., & Ferrés, P. B. S. (2026) · Transplantation Reviews · doi:10.1016/j.trre.2026.101003 · Cited by 2
Timsit, M., Aron‐Wisnewsky, J., Bessède, T., Kassab, D., Amrouche, L., Bento, L., Bertrand, T., Caillard, S., Genser, L., Heng, A.-É., et al. (2026) · The French Journal of Urology · doi:10.1016/j.fjurol.2026.103100 · Cited by 3
Interdisciplinary problem of post-transplant diabetes mellitus: literature review
Владимировна, Б. А., Mustafina, V. R., & Glinkina, I. V. (2021) · Sechenov Medical Journal · doi:10.47093/2218-7332.2021.12.1.60-73 · Cited by 4
Post-transplantation diabetes: Treatment à la carte ?
Benomar, K., Espiard, S., Vahé, C., Mapihan, K. L., Jannin, A., Dharancy, S., Hazzan, M., & Vantyghem, M. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.09.011 · Cited by 2
Pre, peri and posttransplant diabetes mellitus
Essawy, B. E., & KANDEEL, F. R. (2018) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000469 · Cited by 3
Use of Semaglutide in Diabetes Care Post Renal Transplantation
Alluhayyan, O. B., Almutawa, F., Alghamdi, Y. I., Alyousef, K., Altaleb, K. A., Alghamdi, H., & Mahzari, M. M. (2025) · Current Transplantation Reports · doi:10.1007/s40472-025-00463-x · Cited by 1
“In a case series that included five KTR patients using Liraglutide, The Tacrolimus area under the curve (AUC) decreased after the coadministration of liraglutide, However, trough concentrations, tacrolimus doses, and maintenance corticosteroid doses remained stable [34].”
Dalal, N., Saxena, A., Mohsen, A., Borgi, J., Tatum, D. M., & Divya, A. (2026) · JHLT Open · doi:10.1016/j.jhlto.2026.100565 · Cited by 1
Diabetes in Kidney Transplant Recipients
Dhital, S. M. (2018) · Springer eBooks · doi:10.1007/978-3-030-00132-2_10 · Cited by 1
Diabètes post-transplantation rénale
Dubois‐Laforgue, D. (2017) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2017.01.011 · Cited by 1
Management of new onset dysglycemia in transplant recipients
Sharif, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00045-1
Freitas, J. C., Silvano, J., Ribeiro, C., Malheiro, J., Pedroso, S., Almeida, M., Fonseca, I. M., & Martins, L. S. (2024) · Brazilian Journal of Transplantation · doi:10.53855/bjt.v27i1.563_port · Cited by 1
Metadata
- Authors
- Pinelli, N. R., Patel, A., & Salinitri, F. D.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Henry Ford Hospital (US)
- Wayne State University (US)
- Corresponding author
- Patel, Anita
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-09-14
- Volume
- 36
- Issue
- 10
- Pages
- e171-e172
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3781489
- OpenAlex
- W2048952897
- Cited by
- 75
- References
- 5
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 9 · 2023: 4 · 2022: 3 · 2021: 12 · 2020: 11 · 2019: 3 · 2018: 8 · 2017: 1 · 2016: 3 · 2015: 7 · 2014: 1
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- liraglutide, tacrolimus, kidney transplantation, drug-drug interactions, gastric emptying, incretin mimetics, glucocorticoids, type 2 diabetes, drug safety, oral drug absorption
- MeSH terms
- Liraglutide, Adult, Diabetes Mellitus, Humans, Hypoglycemic Agents, Kidney Transplantation, Tacrolimus, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.